-

Eurofins Environment Testing Adds Omicron Variant Detection to its SARS-CoV-2 Monitoring Solution for Wastewater, Surface, Air and Worn Masks

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Environment Testing adds Omicron variant detection capabilities to its commercially available SARS-CoV-2 test portfolio. The Omicron variant has been identified as a ‘variant of concern’ by the World Health Organization (WHO) due to the high number of mutations in the spike protein and indications of high transmissibility.

The monitoring of wastewater, environmental surface, air and worn mask testing, available as part of the Eurofins COVID-19 Sentinel™ and SAFER@WORK™ programs, provides an early warning of the presence of SARS-CoV-2 and its variants amongst large populations or at a given site. This provides crucial information for monitoring viral spread and allows for relevant containment measures to be put in place to avoid an outbreak of the disease even before symptom onset.

Eurofins Environment Testing is able to detect all known SARS-CoV-2 variants in wastewater, air, environmental surfaces and worn masks. Utilizing single point mutations in RT-qPCR, the currently dominant Delta variant can be distinguished from other variants including the new Omicron variant.

For more information, visit EurofinsUS.com/Env.

About Eurofins Environment Testing America
The Eurofins Environment Testing network in the US contributes to a clean and safe environment by providing market-leading laboratory testing, monitoring, and consulting services to a wide range of industrial companies, environmental consultants, contractors, retailers and government authorities.

About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Brian Williams
ir@eurofins.com

Eurofins Scientific

BOURSE:ERF

Release Versions

Contacts

Brian Williams
ir@eurofins.com

More News From Eurofins Scientific

Eurofins: Weekly Report on Share Repurchases From 01st December to 05th December 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/01/2025 FR0014000MR3 20 000 58.9527 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/02/2025 FR0014000MR3 20 000 59.3808 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/0...

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 November 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF EUROFINS SCIENTIFIC SE – E1013 Identity of t...

Eurofins Medical Device Services Launches first GMP PFAS Screening and Testing Solutions for Medical Devices

LANCASTER, Pa.--(BUSINESS WIRE)--Eurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributin...
Back to Newsroom